Increased risk of bleeding with the use of tipranavir boosted with ritonavir in haemophilic patients

Haemophilia

Volumn 14, Issue 1, 2008, Pages 140-141

  Arbuthnot, C ^a   Wilde, J T ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; ENFUVIRTIDE; PROTEINASE INHIBITOR; RITONAVIR; TIPRANAVIR; VIRUS RNA;

ADULT; ARTICLE; AUTOIMMUNITY; BLEEDING TENDENCY; CASE REPORT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG WITHDRAWAL; EPISTAXIS; GINGIVA BLEEDING; HEMARTHROSIS; HEMATOMA; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE CONTUSION; LIVER DYSFUNCTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK REDUCTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

DRUG THERAPY, COMBINATION; HEMOPHILIA A; HEMORRHAGE; HIV INFECTIONS; HUMANS; PYRIDINES; PYRONES; RISK; RITONAVIR;

EID: 37749039471     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01447.x     Document Type: Article

References (5)

1. Racoosin JA, Kessler CM. Bleeding episodes in HIV-positive patients taking HIV protease inhibitors: A case series. Haemophilia 1999; 5: 266-9.
2. Wilde JT. Protease inhibitor therapy and bleeding. Haemophilia 2000; 6: 487-90.
3. Yazdanpanah Y, Viget N, Cheret A et al. Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir. AIDS 2003; 17: 2397-9.
4. Rusconi S, La Seta Catamancio S, Citterio et al. Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000; 44: 1328-32.
5. Ryan CT. New black box warning for ritonavir-boosted tipranavir. AIDS Clin Care, 2006; 18: 72.